Lymphoid cells from genetically-susceptible BALB/c mice immunized against a glycoconjugate of the protozoan parasite, Leishmania major, promote chronic cutaneous disease in BALB/c nude mice. This cell population therefore differs from cells harvested from non-immunized BALB/c mice that are known to be potent mediators of protection against cutaneous leishmaniasis in minimally-reconstituted, syngeneic nude mice. The glycoconjugate when injected into genetically-resistant C57BL/6 mice will increase the size and persistence of cutaneous lesions. Recent studies have established that the water soluble glycoconjugate is derived from a membrane-bound glycolipid that is a receptor used by the parasite in the attachment to macrophages. This glycolipid can protectively immunize mice against cutaneous leishmaniasis. Identification of a vaccinating glycolipid antigen and a suppressogenic component derived from it will greatly facilitate analysis of disease-promoting and resistance-promoting immunity in cutaneous leishmaniasis. However, the fact that a host-protective antigen contains a disease-promoting component may militate against the immediate use of this molecular vaccine in man.
No takes yet. Share an insight, caveat, or question.
Mitchell et al. (1986) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: